Edition:
United Kingdom

Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

37.70USD
7:06pm BST
Change (% chg)

$-0.60 (-1.57%)
Prev Close
$38.30
Open
$38.21
Day's High
$38.24
Day's Low
$37.43
Volume
144,596
Avg. Vol
199,441
52-wk High
$39.45
52-wk Low
$30.20

Chart for

About

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $7,880.51
Shares Outstanding(Mil.): 230.83
Dividend: 1.08
Yield (%): --

Financials

  QGEN.N Industry Sector
P/E (TTM): 104.06 85.68 32.76
EPS (TTM): 0.33 -- --
ROI: 1.87 1.78 14.61
ROE: 2.97 3.27 16.33

BRIEF-HTG Molecular Diagnostics Gets Notice From Qiagen Manchester

* HTG MOLECULAR DIAGNOSTICS SAYS RECEIVED NOTICE FROM QIAGEN MANCHESTER LTD THAT QIAGEN ENDED FIRST STATEMENT OF WORK, DATED JUNE 14, 2017 - SEC FILING Source text: (https://bit.ly/2rW1VKY) Further company coverage:

21 May 2018

BRIEF-Qiagen Reports Q1 Adjusted EPS $0.26

* QIAGEN NV SAYS Q1 REVENUE ROSE 12 PERCENT TO $343.6 MILLION VERSUS AVERAGE. F'CAST FOR $339 MILLION IN REUTERS POLL

02 May 2018

Qiagen beats expectations for Q1 sales and profit growth

May 2 Genetic testing specialist Qiagen NV beat expectations for quarterly sales and profit growth on Wednesday, buoyed by strong demand for its tuberculosis test and companion diagnostics, which match patients with the most effective drugs.

02 May 2018

BRIEF-Qiagen NV Announces European Launch Of Qiastat-Dx

* QIAGEN ANNOUNCES EUROPEAN LAUNCH OF QIASTAT-DX®, A NEXT GENERATION PLATFORM FOR SYNDROMIC INSIGHTS Source text for Eikon: Further company coverage:

19 Apr 2018

BRIEF-Pangaea Oncology Signs Strategic Deal In Oncological Diagnosis With Qiagen

* SAYS SIGNS STRATEGIC AGREEMENT IN ONCOLOGICAL DIAGNOSIS WITH GERMAN DIAGNOSTIC MULTINATIONAL QIAGEN

09 Apr 2018

Earnings vs. Estimates